Osmotica Pharmaceuticals plc - Ordinary Shares (OSMT) Company Bio
Osmotica Pharmaceuticals Plc is a holding company engages in the development and commercialization of specialty products that target markets with underserved patient populations. It offers the M-72, Lorzone which is the chlorzoxazone scored tablets and ConZip which is tramadol hydrochloride extended-release capsules in specialty neurology; and OB Complete, which is the family of prescription prenatal dietary supplements, and Divigel in women's health. The company was founded on July 13, 2017 and is headquartered in Bridgewater, NJ.
OSMT Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Osmotica Pharmaceuticals plc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Osmotica Pharmaceuticals plc ranked in the 8th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Osmotica Pharmaceuticals plc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is -2.22; that's higher than only 15.73% of US stocks in the Healthcare sector that have positive free cash flow.
Its compound free cash flow growth rate, as measured over the past 2.11 years, is -0.31% -- higher than merely 5.08% of stocks in our DCF forecasting set.
56% of the company's capital comes from equity, which is greater than merely 24.6% of stocks in our cash flow based forecasting set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
Want more companies with a valuation profile/forecast similar to that of Osmotica Pharmaceuticals plc? See COO, NVST, TEVA, BHC, and EW.
The FDA has issued a complete response letter ((CRL)) regarding Osmotica Pharmaceuticals (OSMT) new drug application for arbaclofen extended release tablets to treat spasticity resulting from multiple sclerosis. The CRL stated that the Company did not provide adequate justification (including in its most recent NDA amendment) for the statistical analysis of...
Osmotica Pharmaceuticals (OSMT) has lost 20.8% today so far, as SVB Leerink cut its price target after the company announced the receipt of the Complete Response Letter from the FDA for its arbaclofen extended-release tablets to treat spasticity resulting from multiple sclerosis.The new price target of $7 down from the previous $10 reflects...
Shares of Osmotica Pharmaceuticals plunged 25% in Tuesday's after-market trading after the US Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the company's New Drug Application (NDA) for Arbaclofen. Osmotica's (OSMT) NDA was expected to show the clinical efficacy and safety of arbaclofen tablets used in the treatment for patients with spasticity due to multiple sclerosis. Spasticity refers to the condition of stiffening muscles thereby affecting movement, speech and gait.
Shares of Osmotica Pharmaceuticals (NASDAQ: OSMT), a biopharmaceutical company, dropped by as much as 24.4% on Wednesday and closed today's trading session down by 20%. Investors sold off shares of the company following its announcement that the U.S. Food and Drug Administration (FDA) has declined to approve one of its products. Osmotica Pharmaceuticals submitted an amended New Drug Application (NDA) for Arbaclofen ER, a potential treatment for spasticity associated with Multiple Sclerosis (MS), on June 30.